Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 2,427 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9 % sodium chloride Clear all
Withdrawn Phase 4 Interventional

Rescue Quadratus Lumborum Blocks for Post-cesarean Pain

NCT04397458
View directory record Official record
Conditions
Morphine, Analgesics, Analgesics, Opioid, Peripheral Nervous System Agents
Interventions
Saline, Bupivacaine, Dexamethasone
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 17, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Leprosy Skin Test Antigens Trial

NCT00128193
View directory record Official record
Conditions
Leprosy
Interventions
Tuberculin, Purified Protein Derivative, MLSA-LAM, MLCwA, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 17, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 17, 2026, 4:04 PM EDT
Recruiting Phase 2 Interventional

Tocilizumab in Lung Transplantation

NCT06033196
View directory record Official record
Conditions
Lung Transplant
Interventions
Tocilizumab, Placebo for Tocilizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 17, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

NCT04889209
View directory record Official record
Conditions
COVID-19
Interventions
Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
867 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 17, 2026, 4:04 PM EDT
Recruiting Phase 4 Interventional

Evaluation of Lacrifill

NCT07796178
View directory record Official record
Conditions
Dry Eye, Ocular Surface Disease, Cataract Surgery, Eyes Dry Feeling of
Interventions
Lacrifill, Saline
Drug
Lead sponsor
Eye Research Associates, LLC
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Pittsburg, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction

NCT02262078
View directory record Official record
Conditions
Heart Failure
Interventions
Sodium Nitrite Inhalation Solution, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 17, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Skin Quality Improvement

NCT03097835
View directory record Official record
Conditions
Skin Quality
Interventions
Hyper-Diluted Botox, Topical anesthesia, 0.9% saline solution
Drug · Other
Lead sponsor
Steve Yoelin M.D. Medical Associates, Inc.
Other
Eligibility
35 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 17, 2026, 4:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers

NCT03809234
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ondansetron 8mg with Saline & Tariquidar, Ondansetron 16mg with Saline & Tariquidar
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 17, 2026, 4:04 PM EDT
Recruiting Phase 2 Interventional

Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy

NCT03571334
View directory record Official record
Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
IncobotulinumtoxinA (Xeomin®, Merz) (INA), Normal saline
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 17, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Reversal of General Anesthesia With Methylphenidate

NCT02051452
View directory record Official record
Conditions
Post Operative Cognitive Dysfunction, Emergence From Anesthesia
Interventions
Methylphenidate, Saline
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 17, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

NCT03564158
View directory record Official record
Conditions
Healthy
Interventions
meropenem-vaborbactam, Placebo, Moxifloxacin
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 17, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

NCT04652726
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Tucson, Arizona • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 17, 2026, 4:04 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

NCT02802514
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 17, 2026, 4:04 PM EDT
Active, not recruiting Phase 3 Interventional

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117
View directory record Official record
Conditions
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
Interventions
Oregovomab, Paclitaxel, Carboplatin, Placebo
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 17, 2026, 4:04 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, GLSI-100
Biological
Lead sponsor
Greenwich LifeSciences, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
51
States / cities
Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

NCT01409915
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Sagramostim, Saline -- placebo comparator
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 17, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

NCT00009620
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Intracranial Hemorrhages
Interventions
Phenobarbital, Saline
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Female only
Enrollment
610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 1997
U.S. locations
11
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 17, 2026, 4:04 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction

NCT03837470
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
0.9% Sodium Chloride, Furosemide 40 mg
Drug
Lead sponsor
Adhish Agarwal
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 17, 2026, 4:04 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Tranexamic Acid in Adherent Placenta (TAP)

NCT02329756
View directory record Official record
Conditions
Placenta Accreta
Interventions
Tranexamic Acid (TXA), Sodium Chloride 0.9%
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 17, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Glucagon Administration on Energy Expenditure

NCT02237053
View directory record Official record
Conditions
Hyperglucagonemia, Obesity
Interventions
Glucagon, Octreotide, Placebo, Insulin
Drug · Behavioral
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 17, 2026, 4:04 PM EDT
Enrolling by invitation Not applicable Interventional

Cervical Plexus Versus Infiltration for Clavicular Operations (CERPICO)

NCT06737237
View directory record Official record
Conditions
Clavicle Surgery, Clavicle Fracture, Acromioclavicular Joint, Coracoclavicular Ligament
Interventions
cervical plexus block, Local Infiltration Analgesia (LIA)
Procedure
Lead sponsor
Naval Medical Center Camp Lejeune
Federal
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Marine Corps Base Camp Lejeune, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 17, 2026, 4:04 PM EDT
Not yet recruiting Phase 2 Interventional

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

NCT07825857
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Tirzepatide, Placebo (saline)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 17, 2026, 4:04 PM EDT
Terminated Phase 2Phase 3 Interventional

Mindfulness Training Plus Oxytocin Effects on Smoking Behavior

NCT03819231
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Oxytocin, Mindfulness, Saline Solution, Sham mindfulness
Drug · Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 17, 2026, 4:04 PM EDT